TCRX: TScan Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 331.34
Enterprise Value ($M) 169.35
Book Value ($M) 150.87
Book Value / Share 3.15
Price / Book 2.20
NCAV ($M) 70.76
NCAV / Share 1.48
Price / NCAV 4.68

Profitability (mra)
Return on Invested Capital (ROIC) -0.37
Return on Assets (ROA) -0.51
Return on Equity (ROE) -1.14

Liquidity (mrq)
Quick Ratio 6.44
Current Ratio 6.44

Balance Sheet (mrq) ($M)
Current Assets 192.04
Assets 272.15
Liabilities 121.28
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 21.05
Operating Income -93.46
Net Income -89.22

Cash Flow Statement (mra) ($M)
Cash From Operations -61.36
Cash from Investing -60.76
Cash from Financing 135.44

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A K2 HealthVentures Equity Trust LLC 9.98 118.50
02-14 13G/A Lynx1 Capital Management LP 7.80 -4.14
02-09 13G/A Gv 2017, L.p. 2.50 0.00
02-08 13G/A Pitango HealthTech Fund I, L.P. 4.30 92.59
02-07 13G/A Adage Capital Partners Gp, L.l.c. 8.96 -2.50
06-08 13G/A BlackRock Inc. 3.00 -16.30
06-05 13G EcoR1 Capital, LLC 11.70
06-05 13G Biotechnology Value Fund L P 9.99
06-02 13D/A Baker Bros. Advisors Lp 6.50 0.33

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-10 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ T
2024-03-06 10-K Form 10-K
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2023-05-10 10-Q Form 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-18 34,389 98,390 34.95
2024-04-17 299,758 1,642,009 18.26
2024-04-16 17,542 98,778 17.76
2024-04-15 9,301 121,516 7.65

(click for more detail)

Similar Companies
SUPN – Supernus Pharmaceuticals, Inc. TARA – Protara Therapeutics, Inc.
TBPH – Theravance Biopharma, Inc. TENK – TenX Keane Acquisition
TKNO – Alpha Teknova, Inc.


Financial data and stock pages provided by
Fintel.io